Literature DB >> 10726593

Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids.

B Tabarki1, G Ponsot, A M Prieur, M Tardieu.   

Abstract

Thirty-six patients with juvenile dermatomyositis, seen consecutively between 1983 and 1996 and treated initially with low doses of corticosteroids (prednisolone 1 mg/kg/day), were studied retrospectively to evaluate their long-term evolution and to identify factors predictive of the functional outcome. After a mean follow-up of 4.9 years, 28 (78%) of the patients were well without functional impairment; five patients had inactive disease but with persisting disabilities; and three patients had active disease despite several years of treatment. Fifteen children (42%) developed dystrophic calcifications which, in five of these patients, interfered with functions. These patients treated for juvenile dermatomyositis with a low dose corticosteroid regimen had an evolution identical to that of the published series of patients treated with higher doses and probably had a better quality of life. The best predictors of good functional recovery and minimal calcinosis were early treatment after the onset of symptoms and low creatine kinase serum level at the time of diagnosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10726593     DOI: 10.1016/s1090-3798(98)80021-4

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  7 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Favorable outcomes with reduced steroid use in juvenile dermatomyositis.

Authors:  Amir B Orandi; Lampros Fotis; Jamie Lai; Hallie Morris; Andrew J White; Anthony R French; Kevin W Baszis
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-17       Impact factor: 3.054

Review 3.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

4.  Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study.

Authors:  Gail Faller; Bhadrish J Mistry; Mohammed Tikly
Journal:  Pediatr Rheumatol Online J       Date:  2014-01-07       Impact factor: 3.054

5.  Severe juvenile dermatomyositis: two patients complicated with extra musculocutaneous involvement.

Authors:  Ayşe Tosun; Gül Serdaroğlu; Mehmet Tayyip Aslan; Muzaffer Polat; Taner Akalin; Hasan Tekgul; Sarenur Gökben
Journal:  Rheumatol Int       Date:  2006-05-24       Impact factor: 2.631

6.  Clinical characteristics and outcomes of juvenile and adult dermatomyositis.

Authors:  Sang-Jun Na; Seung Min Kim; Il Nam Sunwoo; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

7.  Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.

Authors:  Amir B Orandi; Vikas R Dharnidharka; Noor Al-Hammadi; Kevin W Baszis
Journal:  Pediatr Rheumatol Online J       Date:  2018-12-29       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.